Pfizer Gets CDSCO Panel Nod To Conduct Phase III CT of Rimegepant
New Delhi: Pharmaceutical major Pfizer has received the go-ahead from the Subject Expert Committee (SEC), which is functional under the Central Drug Standard Control Organisation (CDSCO), to conduct the Phase III clinical study of the calcitonin gene- …